Changing the Reference Member State (RMS)

Slides:



Advertisements
Similar presentations
WG 2 (data exchange) During the transitional period and till the Single Authorisation electronic information and communication system is implemented,
Advertisements

Swedish National Board of Trade - Christer Arvíus The Notification Procedure under the WTO/TBT Agreement : An Instrument to prevent New Technical Barriers.
European COoperation in the Field of Scientific and Technical Research Role and rules of procedure for Management Committee Carine Petit Science Officer.
Groupings: Several Type IA or IA IN affecting one MA One Type IA or change affecting several MAs from the same MAH Tightening of specification limits (change.
Peter Davies Licensing Adviser. The Ending of the Individual Licensing Regime All individual telecommunications licenses cease on 25 July 2003 Replaced.
The Mutual Recognition Regulation (EC) 764/2008 Rita L’ABBATE 6th MARS Group meeting Bratislava, 2 October 2008.
EU Cross-Border Care Directive from the Primary Care perspective Results of a simulation Rita Baeten Gothenburg, 3 September 2012.
1 Reform of the EU regulatory framework for electronic communications What it means for Access to Emergency Services Reform of the EU regulatory framework.
EU: Bilateral Agreements of Member States
EU: Bilateral Agreements of Member States. Formerly concluded international agreements of Member States with third countries Article 351 TFEU The rights.
Responding to Inspection Findings
S3: Module D Physikalisch-Technische Bundesanstalt Session 3: Conformity Assessment Module D Peter Ulbig, Harry Stolz Belgrade, 31 October.
Requirements of EU pharmacovigilance legislation for distributors Julia Sipos Quality Management Director Pharmacovigilance coordinator Version 03.
UNECE and OSCE joint event, Almaty, May 2012
THE UK EXPERIENCE RELATED TO ESCITALOPRAM seeking clarity in the EU interest IS THE UK’S REFERRAL TO CHMP UNDER ARTICLE 31 OF DIRECTIVE 2001/83 LEGITIMATE?
European Enforcement Order for uncontested claims JUDr. Radka Chlebcová.
An agency of the European Union Presented by: David Mackay Head of Unit, Veterinary Medicines & Product Data Management Unit Incident Management Plan Veterinary.
1 Mutual Recognition of Driving Disqualifications Liam Dolan Department of Transport.
Service of documents within European Union Regulation (EC) No 1393/2007 of the European Parliament and of the Council of 13 November 2007 on the service.
Implementation of EU Electronic Communication Directives.
1 Workshop on the Directive 96/61/EC concerning (IPPC) Integrated pollution prevention and control INFRA Public participation & access to environmental.
European Commission Rita L’ABBATE Legal aspects linked to internal market DG Enterprise and Industry MARKET SURVEILLANCE COMMUNITY FRAMEWORK UNECE “MARS”
An agency of the European Union Presented by: Emer Cooke and Truus Janse-de Hoog Update on Transparency Progress report from HMA/EMA TF on Transparency.
EUNetPaS is a project supported by a grant from the EAHC. The sole responsibility for the content of this presentation lies with the author(s). The EAHC.
2009/10/06 STUDY ON RECOGNITION OF PROFESSIONAL QUALIFICATIONS Alternative title slide.
Presenters: Promoting Regulatory Excellence Anne-Marie Ryan An Bord Altranais- the Nurses and Midwives Board of Ireland Connecting the Dots II: The European.
HORIZON 2020 Amendments to the Grant Agreement. Consequences The amended provisions become an integral part of the GA All other provisions remain unchanged.
Agreement concerning the adoption of uniform conditions for periodical technical inspections of wheeled vehicles and the reciprocal recognition of such.
Week 12. Lecture 2. Health Law & the EU Cross-border healthcare: patients’ rights.
CLAUDIA PANAIT TAIEX Expert – European Commission Legal Adviser Ministry of Health, ROMANIA.
Compassionate use programs and the European regulatory system Filip Josephson M.D., Ph.D. Clinical Assessor.
The legal aspects of eHealth: the specific case of telemedicine Céline Deswarte ICT for Health Unit, European Commission TAIEX Multi-country seminar on.
Slide 1 The contribution of a world-class regulatory environment to the future of the industry in Ireland Pat O’Mahony Chief Executive, Irish Medicines.
1 PHARMACOVIGILANCE & THE NATIONAL ADVERSE DRUG REACTION (ADR) REPORTING SYSTEM Sarah Spiteri Post-Licensing Directorate Medicines Authority.
An agency of the European Union Guidance on the Submission of Clinical Reports intended for Publication in Accordance with Policy 0070 Principles Industry.
The European Commission´s Tax Transparency Package 18 March 2015.
Chatham House Primer: Professor Sionaidh Douglas-Scott.
1 Package on food improvement agents Food additives Food enzymes Flavourings Common procedure Developments since earlier consultation.
Rose Gyimah International Student Advisor Student Support UK Leaving the European Union July 2016.
Eligibility Process for Cohort 4 & 5 HRA Approval Studies (post CSP) RM&G Lead’s 09 March 2015 Louise Lambert: Non-commercial Research Initiatives.
Co-operating with the European Aviation safety Agency
Vesa Tanner European Commission Directorate-General Energy
SPCs and the unitary patent package
Multinational collaboration in the Authorisation of VMPs: the EU approach VICH Outreach Forum Tokyo, Nov 2017 Noel Joseph European Commission.
“Responsible for Information and Publicity”
Responsible for Information and Publicity Josiane Van der Elst
Brexit Considerations
The Mutual Recognition Regulation
Maintaining joint packaging and labelling into the future
Informal document GRPE-77-21
EU SUBMISSION BY Haripriya & Revathy.
Non-Geographic Porting Process : UK
Engineering Waiver Management
(Follow-up of the discussion at the 66th CA meeting)
DG Environment, Unit D.2 Marine Environment and Water Industry
Czech Republic Settlement Scheme for UK citizens after Brexit
Update on Brexit: - Where are we? - Potential impact?
National Notification Authority
Anne Hayes, Inspection Manager
HPRA preparedness for Brexit
Recommendations to facilitate assessment of new application procedures
Useful points of contact for stakeholders
Variations and Mock-ups
Update on UK participation in Horizon 2020
Pharmacovigilance inspections: what HPRA expects
No Deal EU Businesses Workshop: New Approach goods and the UK marking
Developments related to future EU Nomenclature 14 December 2018
Main S+D Provisions of the WTO-Agreement on Trade Facilitation
ON EUROPEAN TRADEMARKS AND DESIGNS
Client Process Pack.
Presentation transcript:

Changing the Reference Member State (RMS) for a veterinary medicinal product Circumstances for change to RMS In light of the UK referendum of 2016 to leave the EU and the subsequent triggering of Article 50, European competent authorities and industry are working to ensure there is continued access to health products and healthcare for patients across the European network. While the exact details of future relationships are not currently known and will be subject to ongoing negotiations, there will be a need to facilitate the current legislative requirements whereby: a Marketing Authorisation Holder (MAH) must be located within the EU/EEA, and Authorisations through Mutual-Recognition (MR) and Decentralised (DC) procedures must have an RMS based in the EU (2001/82/EC) In a scenario where the UK is viewed as a third country, products currently utilising the UK as an RMS must facilitate a change to another European authority to ensure continued access to the market, with the UK position changing to a Concerned Member State (CMS) role as long they remain within the EU. All transfers are to be fully completed and implemented before the deadline of 30th March 2019. Grounds for a change to RMS do not include circumstances where there is a disagreement between the MAH and the current RMS. Requirements To avoid regulatory confusion, a change to RMS for a veterinary medicinal product cannot take place during a pending procedure. It is therefore advised that any foreseen variations are planned accordingly, and their concerned timetables taken into account. For products where the UK is currently acting as RMS and there is only one CMS, then that CMS must automatically become the new RMS. It is not possible for that member state to refuse this role, even where no prior agreement is in place. This is not an automatic process, and MAH is still required to notify both countries of the required change. Where there are two or more CMS, it is the responsibility of the MAH to secure a new RMS based in the EU/EEA. The choice of a new RMS will be a decision for the MAH subject to agreement with the relevant national competent authority. It is recommended that withdrawals from existing CMS, if any, have been finalised before transfers are initiated. Best Practice Guide for Changing the Reference Member States CMDv/BPG/021 HPRA Brexit Guidance for Stakeholders for Human and Veterinary Medicines How to Change the RMS Where a transfer is to be requested, the MAH should first send an official notification to the current RMS informing them, with justification (e.g. RMS has triggered Article 50 of the Treaty on European Union), of the decision and providing a preferred new RMS. Agreement should be sought from this new RMS for the decision and their availability confirmed. The procedure is handled entirely by the current and proposed RMS and does not require full notification to the existing CMS until the VMP has been successfully transferred. The current RMS will ensure that documentation such as QRD texts, product information and packaging is current for the proposed RMS. The current RMS is also responsible for ensuring the change is recorded in the CTS database. A new procedure number will be created by the proposed RMS, which will be passed to the current RMS for circulation to all CMS, and the CMDv Secretariat via the email, to include a copy of the MAHs notification. Addressing Concerns As per the CMDv Best Practice Guide for Changing the Reference Member States, any generic/hybrid authorisations granted prior to 30 March 2019 in accordance with Directives 2001/82/EC, will continue to be valid authorisations, notwithstanding that the reference product may no longer be authorised in the EU. With a proven track record of conducting high quality and timely assessments, Ireland will be happy to receive requests to act as RMS for all product types including all products for which the UK is currently the RMS and IE is a CMS. There will be no fees charged for switching the RMS from the UK to Ireland. The HPRA commits to an efficient and simple process for handling these requests. If you require any further information, or have any queries regarding changes to RMS, please email vetinfo@hpra.ie and we will be happy to assist you.